References
- Tanaka K, Shimotori T, Makino S, Aikawa Y, Inaba T, Yoshida C, et al. Pharmacological studies of the new antiinflammatory agent3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one. 1st communication: antiinflammatory, analge-sic and other related properties. Arzneimittelforschung 1992;42: 935–44.
- Tanaka K, Shimotori T, Taniguchi Y, Eguchi M, Abe C. Pharma-cological studies on T-614, a novel anti-inflammatory agent: effect on type II collagen-induced arthritis in DBA/1J mice and sponta-neous arthritis in MFtL/1 mice. Int J Immunother 1993;9: 69–78.
- Tanaka K, Yamamoto T, Aikawa Y, Kizawa K, Muramoto K, Matsuno H, et al. Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheu-matoid synovial tissues engrafted into SCID mice. Ftheumatology (Oxf) 2003;42:1365–71.
- Kohno M, Aikawa Y, Tsubouchi Y, Hashiramoto A, Yamada R, Kawahito Y, et al. Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells. J Ftheumatol 2001;28:2591–6.
- Aikawa Y, Yamamoto M, Yamamoto T, Morimoto K, Tanaka K. An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS- and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation. Inflamm Res 2002;51: 188–94.
- Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to delete B lymphocytes. Ftheumatology (Oxf) 2001;40:201–11.
- De Vita S, Zaja F, Sacco S, Dde Candia A, Fanin R, Ferraccioli G. Efficacy of selective B cell blockade in the treatment of rheu-matoid arthritis; evidence for a pathogenetic role of B cells. Ar-thritis Rheum 2002;46;2029–33.
- Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Ftheumatology pre-liminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36: 729–40.
- Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Gold-smith C, et al. American College of Ftheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727–35.
- Inoue T, Kawai S, Azuma T, Asai T, Kondoh S. Proposed standard of clinical trial for antirheumatic drug/therapy by the Drug Evaluation Committee of Japan Rheumatism Foundation. The RYUMACHI 1997;37:516–20.
- Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
- Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983;26:1346–53.
- http://www.meddramsso.com/NewWeb 192003/index.htm
- Hara M, Abe T, Sugawara S, Mizushima M, Hoshi K, Irimajiri S. Efficacy and safety of iguratimod compared with placebo and sala-zosulfapyridine in active rheumatoid arthritis: a controlled, multi-centre, double-blind, parallel-group study. Modern Ftheumatology. 2007;17:1–9
- Tateishi H, Ogawa R, Nakamura T, Murata N, Tanaka S. Evalua-tion of long-term safety and efficacy of leflunomide in Japanese patients with rheumatoid arthritis (in Japanese). J New Remedies Clinics 2003;52(7):932.